This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
PROfound
VISION Trial
mHSPC
ARASENS Trial
nmCRPC
ARAMIS Trial
PSMA PET Imaging
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
Trials in Progress
Trials in Progress
ECLIPSE Trial
Oral EPI-7386
SPLASH Trial
Right Side
PCCTC
DORA
IRONMAN
PROMISE
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Petros Grivas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Kidney Cancer Today
Sumanta (Monty) Kumar Pal, MD
Jaime Landman, MD
Prostate Cancer
Advanced Prostate Cancer
Alicia Morgans, MD, MPH
CRPC with Bone Metastases
Rana R. McKay, MD
Imaging Center
Phillip Koo, MD
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
mHSPC
Alicia Morgans, MD, MPH
nmCRPC
Alicia Morgans, MD, MPH
PSMA-Targeted Therapy
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular, Penile, and Rare GU Malignancies
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Education
Covid-19
The Prostate Cancer Foundation
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Pelvic Health & Reconstruction
Endourology
Testicular Cancer
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
ASCO 2023
AUA 2023
ASCO GU 2023
EAU 2023
All Conferences
View All
PCF
UroToday Home
Recent Abstracts
Urologic Oncology
Prostate Cancer
Recent Abstracts
EAU 2011 - Interest of early confirmatory biopsies and centralized pathological review to select prostate cancer patients for active surveillance - Session Highlights
May 4, 2011
EAU 2011 - Non-invasive diagnosis of prostate cancer from body fluids using a panel of tumor suppressor genes - Session Highlights
May 4, 2011
EAU 2011 - Evaluation of different molecular markers for the detection of minimal residual disease in lymph nodes of patients undergoing radical prostatectomy and extended pelvic lymph node dissection (PLND) - Session Highlights
May 4, 2011
Small prostate size and high grade disease-biology or artifact? - Abstract
May 3, 2011
Inhibition of prostate cancer using RNA interference-directed knockdown of platelet-derived growth factor receptor - Abstract
May 3, 2011
A phase 1/1b study of satraplatin (JM-216) in combination with docetaxel in patients with advanced solid tumors and metastatic castrate-resistant prostate cancer - Abstract
May 3, 2011
Safety and feasibility of image-guided robotic radiosurgery for patients with limited bone metastases of prostate cancer - Abstract
May 3, 2011
Pelvic nodal radiotherapy in patients with unfavorable intermediate and high-risk prostate cancer: Evidence, rationale, and future directions - Abstract
May 3, 2011
Computer-aided analysis of transrectal ultrasound images of the prostate - Abstract
May 3, 2011
Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: Results of a prospective study in a clinical setting - Abstra
May 3, 2011
Pathological findings after radical prostatectomy in men eligible for active surveillance (French trial SURACAP): Is the misclassification rate acceptable? - Abstract
May 3, 2011
Editor's Commentary - Association of obesity with prostate cancer: A case-control study within the population-based PSA testing phase of the ProtecT study
May 3, 2011
EAU 2011 - Open radical prostatectomy (ORP) performed by low volume surgeons predisposes to higher rates of venous thrombosis (VT) and pulmonary embolism (PE) - Session Highlights
May 3, 2011
EAU 2011 - Influence of high dose low molecular weight heparin (LMWH) on blood transfusion and lymphocele rate in open radical prostatectomy - Session Highlights
May 3, 2011
EAU 2011 - Combining screening and chemoprevention of prostate cancer - Session Highlights
May 3, 2011
EAU 2011 - Results from the Gothenburg randomized prostate cancer screening trial - Session Highlights
May 3, 2011
The therapeutic ratio is preserved for radiotherapy or cisplatin treatment in BRCA2-mutated prostate cancers - Abstract
May 2, 2011
Role of principal component analysis in predicting toxicity in prostate cancer patients treated with hypofractionated intensity-modulated radiation therapy - Abstract
May 2, 2011
Avoiding androgen deprivation therapy in men with high-risk prostate cancer: The role of radical prostatectomy as initial treatment - Abstract
May 2, 2011
Prostate cancer treatment ascertained from several sources: Analysis of disagreement and error - Abstract
May 2, 2011
Page 1275 of 1305
Start
Prev
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
Next
End
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free